CLAIMS

1. A uremic toxin adsorbent for oral administration, comprising activated carbon fiber as an active component.

2. The uremic toxin adsorbent for oral administration according to claim 1, wherein the activated carbon fibers have a micropore volume of 0.1 to 2.0 mL/g.

3. The uremic toxin adsorbent for oral administration according to claim 1 or 2, wherein the activated carbon fibers have a fiber length of 15 μm or more and a micropore volume of 0.5 to 1.0 mL/g.

4. The uremic toxin adsorbent according to any one of claims 1 to 3 wherein the activated carbon fiber has a cross-sectional diameter of the fiber of 5 to 50 μm, a fiber length of 15 μm or more, a specific surface area as determined by BET method of 1400 to 2700 m^2/g, a total pore volume of 0.8 to 1.8 mL/g, and a micropore volume of 0.5 to 1.0 mL/g.

5. ~~The~~ Use of the uremic toxin adsorbent for oral administration according to any one of claims 1 to ~~3~~ 4 in the manufacture of a medicament for treating or preventing kidney diseases or dialysis complications.

6. ~~The~~ Use of the uremic toxin adsorbent for oral administration according to ~~any one of~~ claim ~~1 to~~ 4, wherein the adsorbent is to be administered at a daily dose of 1 to 3000 mg.

~~6. An activated carbon fiber having a cross-sectional diameter of the fiber of 5 to 50 μm, a fiber length of 15 μm or more, a specific surface area as determined by BET method of 1400 to 2700 m^2/g, a total pore volume of 0.8 to 1.8 mL/g, and a micropore volume of 0.5 to 1.0 mL/g.~~